Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

@article{Speirs2015PrognosticAP,
  title={Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.},
  author={Valerie Speirs and Giuseppe Viale and Khalid I Mousa and Carlo Palmieri and Sadie Reed and Hanna Nicholas and Maggie Chon U. Cheang and Jacek Jassem and P E L\onning and Eletheria Kalaitzaki and Cornelis J. H. van de Velde and Birgitte Bruun Rasmussen and D M E C Verhoeven and Abeer Adel Mohammed Shaaban and John M. S. Bartlett and J. M. Bliss and R C Coombes},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 9},
  pages={1890-7}
}
BACKGROUND Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. PathIES aimed to assess the potential prognostic and predictive value of ERβ1 and ERβ2 expression in primary tumours in order to determine benefit in the two treatment arms. PATIENTS AND METHODS Primary tumour samples were available for 1256 patients (27% IES population). ERβ1 and ERβ2 expression was… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 2 Excerpts

The role of estrogen receptor-β in breast cancer.

Seminars in reproductive medicine • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…